Online Makale
Online Hizmetlere Toplu Bakış
Toplu Çözüm: JournalAgent
Online Makale Sisteminin Özellikleri
Nasıl Çalışır?
Yetkiler ve Kullanıcı Seçenekleri
JournalAgent:Artıları ve Avantajları
Çalıştığımız Hakemli Dergiler
Kongre Web Sitesi
Online Kayıt ve Konaklama Çözümü:EcomAgent
Elektronik Poster (e-poster)
Online Bilimsel Program ve Ajanda
İnteraktif Konge CD'si
Online Kayıt ve Konaklama
Online Bilimsel Program
Dernekler İçin...
Referanslarımız
Telefon ve e-posta Desteği
Bildiri özeti nedir?
Bildiri özeti nasıl hazırlanır?
Bildiri özeti örnekleri
Kabul mektubu örnekleri
Rheumatology Quarterly
| Rheumatol Q. 2023; 1(1): 0-0 | |||
A triangle: Rheumatoid arthritis, Myasthenia gravis and anti-TNF. Good news or bad news? Long term follow-up: case report and review of literatureEmrah Koç1, Fatih Albayrak1, HANDE ECE OZ1, Bunyamin Kisacik21Gaziantep Dr. Ersin Arslan Training and Research Hospital, Department of Rheumatology, Gaziantep, Turkey2Sanko University Faculty of Medicine, Department of Rheumatology, Gaziantep, Turkey Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized with persistent synovitis, systemic inflammation and the presence of autoantibodies. Inhibitors of tumor necrosis factor (TNF)-alpha are widely used in the treatment of rheumatoid arthritis. However, prolonged use of these agent has been associated with induction some autoimmune disease. Here we have shown that anti-TNF drugs used in long-term follow-up of two patients diagnosed with both rheumatoid arthritis and myasthenia gravis (MG), are safely. Keywords: Rheumatoid arthritis, Myasthenia Gravis, Tumor necrosis factorEmrah Koç, Fatih Albayrak, HANDE ECE OZ, Bunyamin Kisacik. A triangle: Rheumatoid arthritis, Myasthenia gravis and anti-TNF. Good news or bad news? Long term follow-up: case report and review of literature. Rheumatol Q. 2023; 1(1): 0-0 Corresponding Author: Emrah Koç, Türkiye |
| ||
Print
Download citation
RIS
Share with email
Share
Send email to author
PubMed